The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...

The deal, which involves up to 8 “next-generation” weight loss medications and could be worth more than $18 billion, ranks as ...

A spike in M&A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce ...

On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly ...

AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...

Moderna licensed out a rare disease drug for what an analyst called a “modest” sum. Elsewhere, Roche executives suggested better forthcoming obesity results and Summit’s PD-1/VEGF blocker got an FDA ...

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst ...

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...